Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231894 · ClinicalTrials.gov registry record · Phase 4
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
A Phase 4 study, sponsored by Nathan Kline Institute for Psychiatric Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 56
- Enrollment target
NCT00231894 is a Phase 4 study that has completed, run by Nathan Kline Institute for Psychiatric Research. The registered enrollment target is 56 participants.
The verdict
NCT00231894, a Phase 4 study, has completed, sponsored by Nathan Kline Institute for Psychiatric Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a study with an approved drug for treating type 2 diabetes, for its effects on treating glucose and lipid abnormalities in patients being treated with first or second-generation antipsychotics, and comparison of effects of this drug with another treatment lifestyle modification. Patients who meet inclusion criteria will be treated with pioglitazone for 12 weeks. They will be evaluated for fasting glucose and lipids, glucose-tolerance tests, and neurocognitive battery and tests of verbal memory at baseline and during treatment with pioglitazone.
Interventions
- OTHER Placebo
- DRUG Pioglitazone
- BEHAVIORAL Life style diet group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2005-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00231894
The ClinicalTrials.gov registry entry for NCT00231894 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nathan Kline Institute for Psychiatric Research, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00231894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00231894 about?
NCT00231894 is a clinical study titled "Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia". This is a study with an approved drug for treating type 2 diabetes, for its effects on treating glucose and lipid abnormalities in patients being treated with first or second-generation antipsychotics, and comparison of effects of this drug with another treatment lifestyle modification. Patients who...
What is the current status of trial NCT00231894?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 56 participants. The study started on 2005-05. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00231894?
The interventions under investigation include: Placebo (OTHER), Pioglitazone (DRUG), Life style diet group (BEHAVIORAL).
Who is sponsoring clinical trial NCT00231894?
This trial is sponsored by Nathan Kline Institute for Psychiatric Research, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.